(VIANEWS) – Shares of Novavax (NASDAQ: NVAX) fell by a staggering 31.98% in 21 sessions from $9.88 at 2023-02-10, to $6.72 at 11:15 EST on Tuesday, following the last session’s upward trend. NASDAQ is jumping 1.98% to $11,410.76, following the last session’s upward trend.
Novavax’s last close was $6.85, 92% under its 52-week high of $85.60.
About Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Earnings Per Share
As for profitability, Novavax has a trailing twelve months EPS of $-7.27.
Volatility
Novavax’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.44%, a negative 2.49%, and a positive 5.32%.
Novavax’s highest amplitude of average volatility was 2.97% (last week), 5.46% (last month), and 5.32% (last quarter).
Volume
Today’s last reported volume for Novavax is 1450411 which is 83.34% below its average volume of 7834980.
More news about Novavax (NVAX).
